No Influence of Mild-To-Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Ximelagatran, an Oral Direct Thrombin Inhibitor

By Wåhlander K.   Eriksson-Lepkowska M.   Frison L.   Fager G.   Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 755-764

Adis International

Access to resources Recommend Favorite

Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives: Zaleplon, Zolpidem and Zopiclone

By Drover D.R.  

Clinical Pharmacokinetics, Vol. 43, Iss. 4, 2004-01 ,pp. : 227-238

Adis International

Access to resources Recommend Favorite

The Use of Ultra-Short-Acting Opioids in Paediatric Anaesthesia: The Role of Remifentanil

By Davis Peter J.   Cladis Franklyn P.  

Clinical Pharmacokinetics, Vol. 44, Iss. 8, 2005-01 ,pp. : 787-796

Adis International

Access to resources Recommend Favorite

Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin

By Boulton David W.   Li Li   Frevert Ernst U.   Tang Angela   Castaneda Lorna   Vachharajani Nimish N.   Kornhauser David M.   Patel Chirag G.  

Clinical Pharmacokinetics, Vol. 50, Iss. 4, 2011-04 ,pp. : 253-265

Adis International

Access to resources Recommend Favorite

Influence of Severe Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Oral Ximelagatran and Subcutaneous Melagatran

By Eriksson U.G.  

Clinical Pharmacokinetics, Vol. 42, Iss. 8, 2003-01 ,pp. : 743-753

Adis International

Access to resources Recommend Favorite